Abstract
Overview
Introduction
The current Huntington' s disease market is comprised of off-label
prescriptions of psychotropic drugs. In the near term, two pipeline drugs are
set to enter the market, demonstrating the viability of this disease as a
primary marketing indication. In the longer term, with a strong genetic link
and reliable diagnostic test, prophylactic treatment with a disease modifying
drug could prove lucrative.
Scope
- Scenario based analysis and forecasts of the commercial potential of the
Huntington' s disease market to 2016.
- Analysis of patient potential, marketing factors, commercial
attractiveness and clinical attractiveness of key late-stage pipeline drugs.
- Strategic recommendations for maximizing the potential of drugs in this
niche orphan disease market.
- Indication-specific sales forecasts of key pipeline drugs to 2016.
Report Highlights
NeuroSearch' s ACR16 is set to become the market leader by 2010. Targeting a
broad spectrum of symptoms, and possessing a novel mode of action,
neurologists are likely to view this drug favorably when compared to current
treatments.
The launch of Xenazine (tetrabenazine) on the US market and further roll-out
across the 5EU looks set to be a good strategic move by Prestwick
Pharmaceuticals and Cambridge Laboratories. However, peak market penetration
is limited by the drug' s use predominantly in severe patients and its poor
side-effect profile.
Forecasts based on various potential patient population sizes and drug prices,
identify several scenarios in which blockbuster drugs could be established in
this market. A theoretical drug which could achieve this is defined.
Reasons to Purchase
- Access the lucrative potential of this underdeveloped neurodegenerative
disease therapeutic market.
- Benchmark key late-stage compounds against current leading therapies and a
theoretical "ideal" treatment.
- Understand the opportunities in this market based on the comments of
interviewed key opinion leaders and industry executives.
| 
View Cart
